“This donation is a small way to express my admiration for Opportunity Project’s work and its impact on so many lives,” said Dr. Saadi. “As a fellow New Jersey organization, we share a deep commitment ...

The Company’s bylaws establish certain procedural requirements and deadlines that are applicable to annual stockholder meetings, including the 2025 Annual Meeting. A copy of the bylaws can be found at ...

Nyxoah Présente ses Résultats Financiers et d’Exploitation pour le Second Trimestre 2025 La FDA approuve le système Genio® pour le marché américain ; la Société lance la commercialisation du produit ...

WARREN, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today announced that its Founder and CEO, Dr. Ryan Saadi, has donated 10,000 of his ...

Mesa Laboratories, Inc. (NASDAQ: MLAB) (we, us, our, “Mesa” or the “Company”) today announced that it has executed on its previously-announced financial strategy, repaying $97.5 million aggregate ...

The Company remains on track to initiate the HCW9302 clinical trial in the third quarter of 2025. This trial is a first-in-human Phase 1 dose escalation clinical trial to evaluate one of its lead drug ...

Iovance is investigating Amtagvi in frontline advanced melanoma in the Phase 3 trial, TILVANCE-301 (NCT05727904), as well as in additional solid tumor types. About Iovance Biotherapeutics, Inc.